CAJ | 학술논문

目的：观察伊立替康（ CPT－11）节拍式化疗联合索拉非尼（ Sorafenib）对人肝癌细胞HepG2生长的影响及对血管内皮细胞的抑制作用。方法取对数生长的HepG2细胞、人脐静脉内皮细胞（ HUVECs）培养后分组给药：（1）对照组，加培养液。（2）索拉非尼组，6μmol／L。（3）CPT－11（LDM）组，CPT－1130μg／mL。（4）CPT－11（TDM）组，CPT－11160μg／mL。（5）CPT－11（LDM）30μg／mL ＋索拉非尼6μmol／L组。用MTT法检测各实验组人HepG2细胞及HUVECs细胞培养24 h、48 h、72 h后的平均OD值，计算抑制率。结果 CPT－11（ LDM ）组对HepG2细胞抑制作用不明显，明显低于其他实验组（P＜0．05）。 CPT－11（LDM）与索拉非尼联合用药对HUVECs细胞的抑制作用最明显，显著高于单独用药（ P＜0．05）。结论小剂量伊立替康（ CPT－11）体外能够抑制内皮细胞增殖，但对肿瘤细胞HepG2抑制作用有限。靶向治疗联合节拍式化疗效果更佳。
목적：관찰이립체강（ CPT－11）절박식화료연합색랍비니（ Sorafenib）대인간암세포HepG2생장적영향급대혈관내피세포적억제작용。방법취대수생장적HepG2세포、인제정맥내피세포（ HUVECs）배양후분조급약：（1）대조조，가배양액。（2）색랍비니조，6μmol／L。（3）CPT－11（LDM）조，CPT－1130μg／mL。（4）CPT－11（TDM）조，CPT－11160μg／mL。（5）CPT－11（LDM）30μg／mL ＋색랍비니6μmol／L조。용MTT법검측각실험조인HepG2세포급HUVECs세포배양24 h、48 h、72 h후적평균OD치，계산억제솔。결과 CPT－11（ LDM ）조대HepG2세포억제작용불명현，명현저우기타실험조（P＜0．05）。 CPT－11（LDM）여색랍비니연합용약대HUVECs세포적억제작용최명현，현저고우단독용약（ P＜0．05）。결론소제량이립체강（ CPT－11）체외능구억제내피세포증식，단대종류세포HepG2억제작용유한。파향치료연합절박식화료효과경가。
Objective To observe the inhibition effect of low dose CPT-11 combined with Sorafenib on the growth of hu-man heptatic carcinoma strain HepG2 and the proliferation of human umbilical vascular endothelial cells ( HUVECs ) . Methods HUVECs and HepG2 cells were divided into 5 groups: control group, Sorafenib -treated group 6 μmol/L, CPT-11(LDM) -treated group 30 μg/mL, CPT-11(TDM) -treated group 160 μg/mL and Sorafenib+CPT-11 ( LDM)-treated group.The cell proliferation inhibition rate was calculated with MTT assays.Results Both Sorafenib and Low dose CPT-11 can inhibit the proliferation of HUVECs, and the inhibition rate in group sorafenib+CPT-11(LDM)-treated group higher than that in sorafenib group and CPT-11(LDM) group (P<0.05).LDM chemotherapy had little in-hibition effect on HepG2.The inhibition rate to HepG2 in CPT-11(LDM) group was significantly lower than that in others group (P<0.05).Conclusion The anti-tumour effects of Low-dose CPT-11 could be from its angiogenesis inhibition. The combination of Sorafenib and CPT-11(LDM) would be a better choice.